Physician profile
Michelle Tarbox
NPI 1417277807
$177,419.82
in general payments reported to CMS, 2019-2025
37 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $562 · 2021: $1,272 · 2022: $1,338 · 2023: $8,369 · 2024: $48K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $12K · Travel and Lodging: $10K · Grant: $1,000 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,349.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,530.00 |
| Food and Beverage | $12,034.35 |
| Travel and Lodging | $10,224.21 |
| Grant | $1,000.00 |
| Education | $160.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68,171.91 | 2022-2025 | |
| Ucb, INC. | $43,997.39 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $18,755.17 | 2020-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $13,141.70 | 2023-2025 | |
| Eli Lilly and Company | $12,527.55 | 2023-2025 | Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,032.08 | 2022-2025 | Spevigo |
| Abbvie INC. | $1,425.07 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,107.74 | 2020-2025 | Otezla, Otezla, Actimmune |
| Regeneron Healthcare Solutions, INC. | $1,097.30 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $986.19 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $762.42 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Arcutis Biotherapeutics, INC. | $551.44 | 2023-2025 | Zoryve |
| Pfizer INC. | $521.27 | 2019-2025 | |
| Genentech USA, INC. | $342.32 | 2019-2024 | Xolair |
| Leo Pharma INC. | $331.70 | 2022-2025 | Adbry |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $315.43 | 2022-2024 | Sotyktu |
| Incyte Corporation | $293.97 | 2023-2025 | Opzelura |
| Kyowa Kirin, INC. | $247.62 | 2020-2025 | Poteligeo |
| Janssen Scientific Affairs, LLC | $242.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $218.03 | 2024 | Nucala, Arexvy, Trelegy Ellipta |
| Journey Medical Corporation | $178.16 | 2022-2024 | |
| Krystal Biotech INC | $146.39 | 2024-2025 | Vyjuvek |
| Organon LLC | $144.43 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.33 | 2024 | Siliq, Arazlo, Cabtreo |
| Astrazeneca Pharmaceuticals LP | $106.94 | 2021 | |
| Kerecis Limited | $96.14 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Janssen Biotech, INC. | $92.30 | 2024-2025 | Tremfya, Simponi, Stelara |
| Celgene Corporation | $90.52 | 2019 | |
| Dermavant Sciences, INC. | $90.49 | 2023-2024 | Vtama |
| Biofrontera INC. | $70.40 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Tactile Systems Technology INC | $46.33 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $45.33 | 2023 | Dupixent |
| Foundation Medicine, INC. | $32.56 | 2019 | |
| Stemline Therapeutics INC. | $24.47 | 2022 | |
| Chiesi USA, INC. | $22.67 | 2025 | Filsuvez |
| Almirall LLC | $20.09 | 2025 | Klisyri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Tarbox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.